Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :207
Small font sizeDefault font sizeIncrease font size
Navigate Here
     My Preferences 
     Manuscript submission


This article has been cited by
1B-type proto-oncogene-mutated tumors of colon cancer
Sally Temraz,Raafat Alameddine,Ali Shamseddine
Current Opinion in Oncology.2015;27(3)276
2Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis
Qin Fan,Wenhao Lv,Yuexin Xu,Yuan Dong,Zhiqiang Xiang,Junjie Wang
Current Pharmaceutical Design.2020;26(26)3171
3Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
Amartej Merla,Sanjay Goel
Chemotherapy Research and Practice.2012;2012(26)1
4Combined therapeutic efficacy of 188Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells
Molecular and Clinical Oncology.2014;2(3)380
5Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
T Funakoshi,A Latif,M D Galsky
Journal of Human Hypertension.2013;27(10)601
6Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
James Mattina,Benjamin Carlisle,Yasmina Hachem,Dean Fergusson,Jonathan Kimmelman,Lisa Bero
PLOS Biology.2017;15(2)e2000487
7Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
Jamal Joudeh,Joshua E. Allen,Avisnata Das,Varun Prabhu,Michael Farbaniec,Jeffrey Adler,Wafik S. El-Deiry
PLOS Biology.2013;779(2)1
8Risk of Hypertension With Sorafenib Use in Patients With Cancer
XiongWen Yang,Xiong Pan,Xiaoshu Cheng,YuKang Kuang,YingZhang Cheng
American Journal of Therapeutics.2017;24(1)e81
9Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer
Veena A. Thomas,Joseph P. Balthasar
The AAPS Journal.2016;18(4)923
10Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Veena A. Thomas,Joseph P. Balthasar
11Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
Christina Kline,Wafik El-Deiry
12Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
Aviad Zick,Tamar Peretz,Michal Lotem,Ayala Hubert,Daniela Katz,Mark Temper,Yakir Rottenberg,Beatrice Uziely,Hovav Nechushtan,Amichai Meirovitz,Amir Sonnenblick,Eli Sapir,David Edelman,Yael Goldberg,Alexander Lossos,Shai Rosenberg,Iris Fried,Ruth Finklstein,Eli Pikarsky,Hanoch Goldshmidt
13What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Jaume Capdevila,Alfredo Carrato,Josep Tabernero,Enrique Grande
Critical Reviews in Oncology/Hematology.2014;92(2)83
14Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
Miaomiao Gou,Haiyan Si,Yong Zhang,Niansong Qian,Zhikuan Wang,Weiwei Shi,Guanghai Dai
Scientific Reports.2018;8(1)83
15Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
Mhd Yaser Al-Marrawi,Bikramajit Singh Saroya,Matthew C Brennan,Zhaohai Yang,Thomas M Dykes,Wafik S El-Deiry
Cancer Biology & Therapy.2013;14(8)703
16Risk of Treatment-related Mortality with Sorafenib in Patients with Cancer
Xin-Ji Zhang,Tian-Yi Zhang,Fei-Fei Yu,Xin Wei,Ye-Sheng Li,Feng Xu,Li-Xin Wei,Jia He
Asian Pacific Journal of Cancer Prevention.2013;14(11)6681
  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow